About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Envveno Medical Corp (NQ: NVNO )

3.390 +0.040 (+1.19%)
Streaming Delayed Price Updated: 1:16 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Envveno Medical Corp

< Previous 1 2 3 Next >
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
Via ACCESSWIRE
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks — enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public Offering
Via Investor Brand Network
Crude Oil Rises; Onconetix Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing
Via ACCESSWIRE
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
Via ACCESSWIRE
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected
Via Benzinga
Topics Economy
Exposures Interest Rates
Dow Surges Over 100 Points; Costco Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Via ACCESSWIRE
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Via ACCESSWIRE
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
Via ACCESSWIRE
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
Via Benzinga
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Recap: enVVeno Medical Q4 Earnings
Via Benzinga
enVVeno Medical Corporation Announces Proposed Public Offering
Via ACCESSWIRE
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
Via ACCESSWIRE
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
Via ACCESSWIRE
NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024
NVNO stock results show that enVVeno Medical beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Via ACCESSWIRE
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Via ACCESSWIRE
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.